* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:2269N vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Days Payable distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
WuXi Biologics (Cayman)'s Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (MEX:2269N) has a Days Payable of 31.35 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on WuXi Biologics (Cayman) and its competitors. This is 15% below median its historical median of 36.92. Over the past decade, WuXi Biologics (Cayman)'s Days Payable has ranged from 26.50 to 120.20. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #578 out of 707 companies in the Biotechnology industry, placing it in the top 81.8%.
Is WuXi Biologics (Cayman)'s Days Payable too high?
WuXi Biologics (Cayman)'s current Days Payable of 31.35 is 15% below median its 10-year median of 36.92. Over the past 10 years, this metric has ranged from a low of 26.50 to a high of 120.20. The Biotechnology industry median Days Payable is 113.76. WuXi Biologics (Cayman)'s value of 31.35 is 72.4% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #578 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #578 out of 707 companies for Days Payable. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median Days Payable is 113.76. WuXi Biologics (Cayman)'s value of 31.35 is 72.4% below this benchmark. Historically, WuXi Biologics (Cayman)'s own Days Payable has ranged from 26.50 to 120.20 over the past decade. While the company's 10-year median is 36.92 vs. the industry median of 113.76, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Days Payable of 31.35 is 72.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Days Payable is 31.35, which is 15% below median its own 10-year median of 36.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Days Payable of 31.35. The stock's GF Value™ is MXN72.14, compared to a current price of MXN62.53 — trading 13.3% below its estimated fair value. The current Days Payable is 31.35, which is 15% below median its 10-year median of 36.92 and 72.4% below the Biotechnology industry median of 113.76. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Days Payable is 31.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.
Key valuation signals for MEX:2269N:
Days Payable: 31.35 (15% below median its 10-year median of 36.92)
GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
Industry Position: 72.4% below the Biotechnology median (#578 of 707)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score
Get the complete analysis for MEX:2269N
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
